ReviewBreast cancer (Dove Medical Press)2024
Recent Advances in Immunotherapy for Breast Cancer: A Review.
Review in Breast cancer (Dove Medical Press), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Dual Role of LBH589 in Triple-Negative Breast Cancer: Inhibition of Tumor Growth and Enhancement of Antitumor Immunity.Cancer reports (Hoboken, N.J.) · 2026Article
- Role of ferroptosis on immunotherapy in breast cancer.Molecular biology reports · 2026Review
- JAK/STAT-mediated regulation of PD-L1 expression in breast cancer: Molecular mechanisms and implications for immunotherapy.iScience · 2026Review
- Current Developments of CAR-T and CAR-NK Cell Therapies for Ovarian Cancer.Stem cell reviews and reports · 2026Review
- The puppet master in the breast cancer "microecological community": spatial and metabolic regulation of macrophage heterogeneity.Molecular cancer · 2026Review
- The role and research progress of FGF21 in breast cancer: a review.Frontiers in oncology · 2026Review
- Chinese medicine-based interventions in triple-negative breast cancer: mechanistic evidence, clinical findings, and translational challenges-a narrative review.Frontiers in pharmacology · 2026Review
- Lon peptidase 1 promotes proliferation and metastasis in breast cancer via interleukin 6 signaling.Discover oncology · 2025Article
- Computational Analysis of Exosome-Derived Signature in TNBC: Integrating Single-Cell and Bulk Transcriptomics for Prognosis Prediction.Clinical and translational science · 2025Article
- Small molecule inhibitors for treating breast cancer: drug analysis based on the pathogenesis of breast cancer.Future medicinal chemistry · 2025Review
- Bioinformatics analysis of innovative multi-epitope vaccine utilizing MAGE-A, MAM-A, and Gal-3 for breast cancer management.Scientific reports · 2025Article
- Exploring the Mechanism of Lianqiao Jinbei Decoction Inhibiting HER2-Positive Breast Cancer Based on Network Pharmacology and Experimental Verification.Breast cancer (Dove Medical Press) · 2025Article
- Review
- Use of traditional Chinese medicine bezoars and bezoar-containing preparations in hepatocarcinoma.World journal of gastrointestinal oncology · 2024Article
- mScientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is one of the most common malignant tumors in women in the world, and its incidence is increasing year by year, which seriously threatens the physical and mental health of women. Triple negative breast cancer (TNBC) is a special molecular type of breast cancer in which estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 are negative. Compared with other molecular types of breast cancer, triple-negative breast cancer (TNBC) has high aggressiveness and metastasis, high recurrence rate, lack of effective therapeutic targets, and usually poor clinical treatment effect. Chemotherapy was the main therapeutic means used in the past. With the advent of the immune era, immunotherapy has made a lot of progress in the treatment of triple-negative breast cancer (TNBC), bringing new therapeutic hope for the treatment of triple-negative breast cancer. This review combines the results of cutting-edge medical research, mainly summarizes the research progress of immunotherapy, and summarizes the main treatment methods of triple-negative breast cancer (TNBC) immunotherapy, including immune checkpoint inhibitors, tumor vaccines, adoptive immunotherapy and the application of traditional Chinese and western medicine. It provides a new idea for the treatment of triple negative breast cancer (TNBC).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.